Lee Ratner
Overview
Explore the profile of Lee Ratner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
138
Citations
3089
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Krishnamurthy A, Wang H, Rhee J, Davar D, Moy R, Ratner L, et al.
Cancer Chemother Pharmacol
. 2025 Jan;
95(1):27.
PMID: 39841295
Background: ATR is an apical DDR kinase activated at damaged replication forks. Elimusertib is an oral ATR inhibitor and potentiates irinotecan in human colorectal cancer models. Methods: To establish dose...
2.
Pokhrel N, Panfil A, Habib H, Seeniraj S, Joseph A, Rauch D, et al.
J Extracell Vesicles
. 2024 Oct;
13(10):e12516.
PMID: 39385703
Adult T cell leukaemia (ATL), caused by infection with human T- lymphotropic virus type 1 (HTLV-1), is often complicated by hypercalcemia and osteolytic lesions. Therefore, we studied the communication between...
3.
Joseph A, Cheng X, Harding J, Al-Saleem J, Green P, Veis D, et al.
bioRxiv
. 2024 Jun;
PMID: 38853836
During HTLV-1 infection, the virus integrates into the host cell genome as a provirus with a single CCCTC binding protein (CTCF) binding site (vCTCF-BS), which acts as an insulator between...
4.
Auberle C, Wu N, Dipersio J, Waqar S, Ratner L
Acad Med
. 2024 May;
100(1):38-41.
PMID: 38814121
Problem: Several barriers to physicians becoming clinical investigators exist, including inexperience, lack of available mentors, and inconsistent instructive approaches with varying degrees of participation during training. These barriers cause fewer...
5.
Pokhrel N, Panfil A, Habib H, Seeniraj S, Joseph A, Rauch D, et al.
bioRxiv
. 2024 Mar;
PMID: 38496506
Adult T cell leukemia (ATL), caused by infection with human T cell leukemia virus type 1 (HTLV-1), is often complicated by hypercalcemia and osteolytic lesions. Therefore, we studied the communication...
6.
Tu J, King E, Maksimova V, Smith S, Macias R, Cheng X, et al.
J Virol
. 2024 Jan;
98(2):e0162323.
PMID: 38193692
Human T-cell leukemia virus type 1 (HTLV-1) is a retrovirus responsible for adult T-cell leukemia/lymphoma, a severe and fatal CD4+ T-cell malignancy. Additionally, HTLV-1 can lead to a chronic progressive...
7.
Rajdev L, Jackie Wang C, Joshi H, Lensing S, Lee J, Ramos J, et al.
Cancer
. 2023 Nov;
130(6):985-994.
PMID: 37962072
Background: Although immunotherapy has emerged as a therapeutic strategy for many cancers, there are limited studies establishing the safety and efficacy in people living with HIV (PLWH) and cancer. Methods:...
8.
Wang-Gillam A, Lim K, McWilliams R, Suresh R, Lockhart A, Brown A, et al.
Clin Cancer Res
. 2023 Nov;
29(22):4698.
PMID: 37960920
No abstract available.
9.
Rubinstein P, Moore P, Bimali M, Lee J, Rudek M, Chadburn A, et al.
Lancet Haematol
. 2023 Aug;
10(8):e624-e632.
PMID: 37532416
Background: Brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine (AVD) is approved in the upfront setting for advanced stage classical Hodgkin lymphoma (cHL). People living with HIV have been...
10.
Haigentz Jr M, Lee J, Chiao E, Aboulafia D, Ratner L, Ambinder R, et al.
Clin Cancer Res
. 2023 Jul;
29(24):5038-5046.
PMID: 37523145
Purpose: To evaluate the safety, pharmacokinetics, and pharmacodynamic effects of cabozantinib, a CYP3A4 substrate, in people living with human immunodeficiency virus and cancer receiving antiretrovirals (ARV). Patients And Methods: Patients...